QUEBEC CITY, Nov. 6 /PRNewswire/ -- Infectio Diagnostic Inc. (IDI), and Cepheid have just concluded new agreements to better serve their respective interests. At the same time they are terminating the current ARIDIA joint venture. These new agreements will enable IDI and Cepheid increasing the synergy between their technologies and providing each company greater flexibility in building and operating their businesses.
The summary of these new agreements is :
- IDI receives worldwide rights to distribute Cepheid's Smart Cycler(R)
for use with IDI's assays.
- IDI will be able to independently develop its own menu of assays on
the real time PCR platform, the Smart Cycler(R), manufactured and
supplied by Cepheid.
- IDI receives worldwide rights to sell the complete system through its
own distribution network.
- Cepheid receives non-exclusive worldwide distribution rights for
several IDI assays mainly : IDI-Strep B(TM), IDI-MRSA(TM) and
IDI-VRE(TM), which are configured for use with Cepheid's Smart
Cycler(R). Moreover, Cepheid will get a license to apply some IDI's
proprietary target sequences for its own assays to be performed on
Cepheid's GeneXpert system.
"These new agreements increase the competitive advantage and strength of each company", says Jean-Pierre Gayral, President and Chief executive officer by interim. IDI and Cepheid have already demonstrated the capability of working together. They got a first FDA approved assay claiming culture replacement with IDI-Strep B(TM), and are expecting their second product, IDI- MRSA(TM), which will detect MRSA directly from clinical specimens. This product has just been filed with the regulatory agencies.
IDI is very confident that this new relationship with Cepheid will accelerate their successes on this competitive market.
INFECTIO DIAGNOSTIC INC.
CONTACT: Karina Jackson, Events Coordinator, Sales &Marketing, Office: (418) 681-4343, extension 234, Cellphone: (418) 284-2613